Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial
Titel:
Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial
Auteur:
Kim, D. Huber, R. Ahn, M. Langer, C. Tiseo, M. West, H. Groen, H. Reckamp, K. Hochmair, M. Leighl, N. Hansen, K.H. Gettinger, S. Paz-Ares Rodriguez, L. Kim, E. Smit, E. Kim, S. Reichmann, W. Kerstein, D. Camidge, D.R.